KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stratasys (SSYS) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Stratasys (SSYS) over the last 12 years, with Q3 2025 value amounting to $71.5 billion.

  • Stratasys' Cash & Equivalents rose 11164870.22% to $71.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $71.5 billion, marking a year-over-year increase of 11164870.22%. This contributed to the annual value of $70.2 million for FY2024, which is 1499.67% down from last year.
  • Per Stratasys' latest filing, its Cash & Equivalents stood at $71.5 billion for Q3 2025, which was up 11164870.22% from $71.1 million recorded in Q2 2025.
  • In the past 5 years, Stratasys' Cash & Equivalents ranged from a high of $71.5 billion in Q3 2025 and a low of $64.0 million during Q3 2024
  • Its 5-year average for Cash & Equivalents is $3.9 billion, with a median of $150.5 million in 2022.
  • In the last 5 years, Stratasys' Cash & Equivalents crashed by 5644.57% in 2024 and then surged by 11164870.22% in 2025.
  • Stratasys' Cash & Equivalents (Quarter) stood at $243.2 million in 2021, then crashed by 38.12% to $150.5 million in 2022, then plummeted by 45.12% to $82.6 million in 2023, then dropped by 15.0% to $70.2 million in 2024, then surged by 101709.12% to $71.5 billion in 2025.
  • Its Cash & Equivalents was $71.5 billion in Q3 2025, compared to $71.1 million in Q2 2025 and $70.1 million in Q1 2025.